medric medric
[닫기]
잠시만 기다려 주세요. 로딩중입니다.

Body Cavity?Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma

Cancer Research and Treatment 2019년 51권 4호 p.1302 ~ 1312
 ( Shin Jung-Hoon ) - Seoul National University Hospital Department of Internal Medicine

 ( Ko Young-Hyeh ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Pathology
 ( Oh Sung-Yong ) - Dong-A University College of Medicine Department of Internal Medicine
 ( Yoon Dok-Hyun ) - University of Ulsan College of Medicine Asan Medical Center Department of Oncology
 ( Lee Jeong-Ok ) - Seoul National University Bundang Hospital Department of Internal Medicine
 ( Kim Jin-Seok ) - Yonsei University College of Medicine Department of Internal Medicine
 ( Park Yong ) - Korea University Anam Hospital Department of Internal Medicine
 ( Shin Ho-Jin ) - Pusan National University Hospital Department of Internal Medicine
김석진 ( Kim Seok-Jin ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Medicine
 ( Won Jong-Ho ) - Soonchunhyang University Seoul Hospital Department of Internal Medicine
 ( Yoon Sung-Soo ) - Seoul National University Hospital Department of Internal Medicine
 ( Kim Won-Seog ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Medicine
고영일 ( Koh Young-Il ) - Chonnam National University Hospital Department of Internal Medicine

Abstract


Purpose: Primary effusion lymphoma (PEL) is a type of body cavity?based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden.

Materials and Methods: We retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea.

Results: Latency-associated nuclear antigen 1 (LANA1) immunostaining indicated that six patients had PEL, six patients had human herpesvirus 8 (HHV8)-unrelated BCBL, and five patients had HHV8-unknown BCBL. The patients with PEL exhibited no evidence of immunodeficiency except for one who was HIV positive. One (20%) and four (80%) patients with PEL and six (100%) and zero (0%) patients with HHV8-unrelated BCBL were positive for CD20 and CD30 expression, respectively. The two patients with PEL (one HIV-positive and one HIV-negative patient) with the lowest proliferation activity as assessed by the Ki-67 labeling index survived for > 1 and > 4 years without chemotherapy, respectively, in contrast to the PEL cases in the literature, which mostly showed a high proliferation index and poor survival.

Conclusion: PEL mostly occurred in ostensibly immunocompetent individuals and had a favorable outcome in Korea. A watchful waiting approach may be applicable for managing HIV-seronegative patients with PEL with a low Ki-67 labeling index. A possible trend was detected among LANA1, CD20, and CD30 expression in BCBL.

키워드

Body cavity-based lymphoma; Primary effusion lymphoma; Human herpesvirus 8; Human immunodeficiency virus; Immunophenotype
원문 및 링크아웃 정보
  
등재저널 정보
SCI(E)
MEDLINE
KCI
KoreaMed
KAMS